CAFs also produce IGF2 that binds to the IGF1 receptor in lung cancer cells and activate the AKT/Sox2 pathway, leading to enhanced expression of P glycoprotein (PG-P), a member of the ATP-binding cassette transporters, that is capable of pumping out the chemotherapeutic drug [43]. Here, SOX2 is linked to lung carcinoma.